KalVista Pharmaceuticals to present phase-3 sebetralstat data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from 23-26 February 2024.
The following presentations will take place on Saturday 24 February 2024 from 9:45-10:45am Eastern Time (ET) in the Convention Center, Level 2, Hall D.
- Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users (#215): Bob Geng, Vibha Desai, Julie Ulloa, Sherry Danese, Shawn Czado, Paul K. Audhya, Timothy Craig. Results shared as an oral poster presentation and Q&A
- Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers (#216): Sandra Christiansen, Maeve O’Connor, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Paula Busse. Results shared as an oral poster presentation and Q&A Anxiety
- Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks (#257): James Wedner, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Sandra Christiansen. Results shared as an oral poster presentation and Q&A
- Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment (#258): Daniel F. Soteres, Anete S. Grumach, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Autumn Burnette. Results shared as an oral poster presentation and Q&A
- Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks (#260): Princess Ogbogu, Hilary Longhurst, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Ricardo Zwiener. Results shared as an oral poster presentation and Q&A
- The Impact of On-demand Treatment on Quality of Life of People with HAE (#265): Paula Busse, Bob Geng, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Douglas H. Jones. Results shared as an oral poster presentation and Q&A
- Characterizing the Perspective of Patients with HAE on Prophylactic Treatment (#270): Stephen Betschel, Cristine Radojicic, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, William Lumry. Results shared as an oral poster presentation and Q&A
- Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack (#284): Constance Katelaris, Michael Manning, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, William Lumry. Results shared as an oral poster presentation and Q&A
The following late-breaking presentation will take place on Sunday 25 February 2024 from 9:45-10:45am ET in the Convention Center, Level 2, Hall D.
- Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebocontrolled Phase 3 KONFIDENT Trial (L45): Marc Riedl, Emel Aygören-Pürsün, William Lumry, Henriette Farkas, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Paul K. Audhya, Jonathan Bernstein, Marcus Maurer, Danny Cohn
(Source: KalVista)
